If you have been reading about somatotroph and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-29. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
== Diagnosis == In order to assess lactose intolerance, intestinal function is challenged by ingesting more dairy products than can be readily digested. Clinical symptoms typically appear within 30 minutes, but may take up to two hours, depending on other foods and activities. Substantial variability in response (symptoms of nausea, cramping, bloating, diarrhea, and flatulence) is to be expected, as the extent and severity of lactose intolerance varies among individuals. The next step is to determine whether it is due to primary lactase deficiency or an underlying disease that causes secondary lactase deficiency. Physicians should investigate the presence of undiagnosed celiac disease, Crohn's disease, or other enteropathies when secondary lactase deficiency is suspected and infectious gastroenteritis has been ruled out. Lactose intolerance is distinct from milk allergy, an immune response to cow's milk proteins. They may be distinguished in diagnosis by giving lactose-free milk, producing no symptoms in the case of lactose intolerance, but the same reaction as to normal milk in the presence of a milk allergy. A person can have both conditions. If positive confirmation is necessary, four tests are available.
An early attempt in the direction of elastic-plastic fracture mechanics was Irwin's crack extension resistance curve, Crack growth resistance curve or R-curve. This curve acknowledges the fact that the resistance to fracture increases with growing crack size in elastic-plastic materials. The R-curve is a plot of the total energy dissipation rate as a function of the crack size and can be used to examine the processes of slow stable crack growth and unstable fracture. However, the R-curve was not widely used in applications until the early 1970s. The main reasons appear to be that the R-curve depends on the geometry of the specimen and the crack driving force may be difficult to calculate.
=== Mood disorders === In the case of mood disorders, specifically bipolar disorder, it is hypothesized that N-acetyl-cysteine (NAC), acetyl-L-carnitine (ALCAR), S-adenosylmethionine (SAMe), coenzyme Q10 (CoQ10), alpha-lipoic acid (ALA), creatine monohydrate (CM), and melatonin could be potential treatment options.
== Production process == Stock cubes are made by mixing already-dry ingredients into a paste, including salt, fat, (meat/bone/vegetable) extract, etc. The ingredients are usually mixed in a container (batch mixing), left to mature, and then shaped into the cube form. Alternatively, they can be mixed directly into an extruder. The "extract" portion needs to be separately produced from the meat, bone, or whatever food is intended to be used in the reconstituted boullion (see meat extract). This is achieved by large-scale cooking similar to what is used to make pre-packaged broth, followed by an evaporation process to condense the product.
Sources: en.wikipedia.org
== History == The study of extracellular metabolites has been prevalent in scientific literature. However, global exometabolite profiling was only realized with recent advances allowing for improved chromatographic separation and detection of hundreds to thousands of compounds by the mid-2000s. The first work to demonstrate the biological relevance of comparative profiling of exometabolite pools was not until 2003, when the term "metabolite footprinting" was coined by Jess Allen and coworkers. This work attracted a great deal of interest in the community, particularly for characterization of microbial metabolism. The idea of the "exometabolome" encompassing the components of the exometabolite pool was not introduced until 2005. Recent advances in mass spectrometry imaging have allowed for spatial localization of released metabolites. As the field of microbiology becomes increasingly more centered on microbial community structure, exometabolomics has provided for rapid understanding of metabolic interactions between two or more species. Recently, exometabolomics has been used to design co-culture systems. Because the analysis of extracellular metabolites allows for the predictions and determinations of metabolite exchange, exometabolomics analyses can be used for understanding community ecological networks.
Norbert Elias; (1897-1990) sociologist especially famous for theory of civilising/decivilising processes; was deeply involved in the German Zionist movement, and acted as one of the leading intellectuals within the German-Jewish youth movement "Blau-Weiss" (Blue-White). Elias' most famous work is The Civilizing Process Samantha Ellis is an Iraqi Jewish British playwright and writer best known for her books How to be a Heroine, Chopping Onions on My Heart, and her play How to Date a Feminist. Richard Ellmann literary scholar and biographer Aaron Esterson (23 September 1923 – 15 April 1999) prolific author and psychiatrist who was one of the founders of the Philadelphia Association along with R. D. Laing, with whom he wrote Sanity, Madness, and the Family. He wrote four other scholarly texts on psychiatry and existentialism as well as countless academic papers and monographs. Hans Eysenck (4 March 1916 – 4 September 1997); author of over fifty books and numerous academic papers; of German Jewish maternal lineage; psychologist best remembered for his work on intelligence and personality, although he worked on other issues in psychology. At the time of his death, Eysenck was the most frequently cited living psychologist in the peer-reviewed scientific journal literature. Henry Ezriel (c1910-1985) was a Kleinian analyst and author who pioneered group analysis at the Tavistock Clinic; best known as the originator of one of the Malan triangles; worked alongside W. R. Bion as consultant psychiatrist to the Tavistock.
Rodney Smith Markin (born 1956), is an American pathologist and authority in the field of laboratory automation. In 1993, he designed and created one of the world's first automated clinical laboratory specimen, device and analyzer management systems. In the mid-1990s, he chaired a standards group called the Clinical Testing Automation Standards Steering Committee (CTASSC) of the American Association for Clinical Chemistry, which later evolved into an area committee of the Clinical and Laboratory Standards Institute. Markin serves as the Vice President for Business Development and practices pathology at Nebraska Medicine, is associate vice chancellor for business development for the University of Nebraska Medical Center, and executive director of the UNeTech Institute of the University of Nebraska Medical Center and the University of Nebraska Omaha. He serves as both the David T. Purtilo Professor in the Department of Pathology and Microbiology in UNMC's College of Medicine as well as the Executive Director of the UNeTech Institute. Prior to his current position, he was the chief operating officier of the University of Nebraska system, the chief technology officer at UNMC, interim dean of the UNMC College of Medicine, board chairman and president and CEO of the Nebraska Medicine clinical practice plan (fka UNMC Physicians), an academic medical practice which includes more than 750 physicians, and has held several other administrative and academic positions at the University of Nebraska Medical Center.
Nalbuphine, sold under the brand names Nubain among others, is an opioid analgesic which is used in the treatment of pain. It is given by injection into a vein, muscle, or fat. Side effects of nalbuphine include sedation, sweatiness, clamminess, nausea, vomiting, dizziness, vertigo, dry mouth, and headache. Unlike other opioids, it has little to no capacity to cause euphoria or respiratory depression. There is also little to no incidence of dysphoria, dissociation, hallucinations, and related side effects at typical therapeutic doses. Nalbuphine is a mixed agonist/antagonist opioid modulator. Specifically, it acts as a moderate-efficacy partial agonist or antagonist of the μ-opioid receptor (MOR) and as a high-efficacy partial agonist of the κ-opioid receptor (KOR), whereas it has relatively low affinity for the δ-opioid receptor (DOR) and sigma receptors. Nalbuphine was patented in 1968 and was introduced for medical use in the United States in 1979. It is marketed in many countries throughout the world.
=== Carrier Residential === Carrier Residential provides heating, cooling, and indoor air quality solutions for single-family homes and multi-family residences. Its portfolio includes energy-efficient air conditioners, furnaces, heat pumps, and smart thermostats designed to enhance comfort while helping lower energy bills. Carrier Residential supports homeowners through a network of Factory Authorized Dealers to ensure reliable installation and maintenance.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.